MADRID (Reuters) - Spanish biotech Pharma Mar PHMR.MC booked a 131 million euro ($152.84 million) net profit in the first nine months of the year thanks to a payment from drug maker Jazz Pharmaceuticals JAZZ.O to market a drug in Canada, Pharma Mar said on Tuesday.
Jazz Pharmaceuticals paid 300 million dollars to Pharma Mar during the period as part of a commercial agreement to market its cancer drug Lubrinectedin in Canada, Pharma Mar said.
Pharma Mar posted a 27 million euro loss in the first nine months of 2019.
($1 = 0.8571 euros)
Reporting by Inti Landauro; Nathan Allen
Our Standards: The Thomson Reuters Trust Principles.